Brain Tumor Vaccine Delivers 66% Eight-Year Survival in 33-Patient Study
Updated
Updated · DW (English) · Jul 8
Brain Tumor Vaccine Delivers 66% Eight-Year Survival in 33-Patient Study
1 articles · Updated · DW (English) · Jul 8
Summary
Eight years after treatment, 66% of 33 patients with high-grade astrocytomas were still alive and 42% had no tumor recurrence, according to long-term results published in Nature.
The therapeutic vaccine targets an IDH1 mutation found in grade 3 and 4 astrocytomas, prompting both T-cell and antibody responses to attack residual tumor cells after radiochemotherapy.
Researchers and outside specialists called the findings encouraging because these tumors usually recur at an almost 100% rate, but they warned the small, uncontrolled study cannot prove effectiveness.
More than 200 patients are due to enter a randomized follow-up trial in March 2027, with reliable results not expected for about nine years.
This brain tumor vaccine targets one mutation. What hope exists for patients who do not have it?
Vaccine, targeted drug, or CAR-T cell: which new therapy holds the most promise for aggressive brain cancer?
2026 Brain Tumor Vaccine Advances: Clinical Trial Results, Survival Metrics, and the Future of Glioblastoma Treatment
Overview
As of July 2026, brain tumor treatment is advancing rapidly, especially with new therapeutic vaccines showing promise in clinical trials. A major breakthrough is the upcoming Phase I trial of a gene therapy-based vaccine for newly diagnosed glioblastoma patients. This vaccine works by delivering genetic material to tumor cells, causing them to produce specific antigens that trigger a strong immune response. The main goal of the trial is to test the vaccine’s safety and tolerability, while early results offer hope for better outcomes in aggressive brain tumors like glioblastoma.